Consider This from NPR - How HIV researchers overcame setbacks and kept a vaccine trial going

Episode Date: January 22, 2026

Scientists say research into a vaccine for HIV is further along than it’s ever been.But Trump administration cuts to scientific research have set that effort back.Including a promising trial for an HIV vaccine in Africa – which was shut down altogether.NPR’s Ari Daniel has the story of how researchers there refused to give up.Ari’s reporting for this story was supported by a grant from the Pulitzer Center. The Gates Foundation is a financial supporter of NPR. This episode was produced by Mallory Yu and Kira Wakeam.It was edited by Rebecca Davis and Courtney Dorning.Our executive producer is Sami Yenigun. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

During his first term, President Trump made this bold proposal during a state of the union address. My budget will ask Democrats and Republicans to make the needed commitment to eliminate the HIV epidemic in the United States within 10 years. We have made incredible strides. For decades, eliminating AIDS has depended in part on the development of a vaccine. The Trump administration's goal of eliminating the virus in the U.S. led to a swell of research into a vaccine and funding for AIDS relief, both in the U.S. and around the globe. HIV research has been in place since the discovery of the virus is the cause of advanced HIV disease, which we used to call AIDS. That's John Brooks, former chief medical officer to the CDC's division of HIV prevention. We are now at a place due to consistent funding,

through mostly federal support that's discovered amazing drugs that can help us both treat HIV to keep a person healthy, but also to prevent HIV. Then during his second term, President Trump slashed thousands of public health jobs and gutted funding for scientific research, including grants and funds for developing an HIV vaccine and treating AIDS. The administration also suspended funding for global AIDS relief programs. leaving scientists around the globe worried for the future of their research. A vaccine would be incredible if we could have it. Enormous public health impact, gigantic economic benefits, as well as the scientific advancements it will provide and has provided in the past. Ditto for an HIV cure.

Consider this. An ambitious and promising vaccine trial in Africa was supposed to launch a year ago. When the Trump administration cut funding, researchers like infectious disease specialist Linda Gail Becker had to pivot. This matters too much to not finish the work. Now a paired down trial is getting underway. From NPR, I'm Juana Summers. This message comes from Wise, the app for international people using money around the globe.

You can send, spend, and receive in up to 40 currencies with only a few simple taps. Be smart, get Wise. Download the Wise app today or visit wise.com. Tees and Cs apply. This message comes from data bro. The Data and AI company. AI agents work best when they have the right context. Your unique data, your rules, your workflows.

Agent Bricks helps companies build agents that are accurate, continuously learning, and automate everyday tasks. It's AI built for how your business actually runs. Agent Bricks by Data Bricks. AI agents grounded in your data and built for your goals. This week on the MPR Politics Podcast. President Trump's first year. You know, it's not just that there aren't really the guardrails on Trump's presidency this term. It's that he's doing things that are just not conservative.

We unpack the ongoing transformation of the Republican Party on the NPR Politics Podcast. Listen on the NPR app or wherever you get your podcasts. It's consider this from NPR. Scientists say research into a vaccine for HIV is further along than it's ever been. but Trump administration cuts to scientific research have set that effort back, including a promising trial for an HIV vaccine in Africa, which was shut down altogether. NPR's Ari Daniel has the story of how researchers there refuse to give up. Penny Moore leads me into a room at the National Institute for Communicable Diseases in Johannesburg.

It's a raid with half a dozen large green and white freezers. These are the freezers that contain samples that are the basis of everything we do in the lab. Moore is a virologist at the University of Vatarsrand. She cracks open the lid of one of the freezers and pulls out a tower of frosty tubes. It's heavy and hard for me to lift. So this is blood and cells. All samples that have been donated over and over again for two decades by the same group of 117 South African women.

They live in the communities that are most ravaged by HIV, and they donate their samples because they hope to see an end to an epidemic that is really, really real for them. These samples have helped Moore and her team piece together a detailed portrait of the virus over the years, how it infects, how it hides, and how much it changes across different parts of the world and even within a single individual.

The amount we have learned from these freezes, it's just astonishing. And yet Moore spent much of last year worrying that it might all amount to nothing, because just when she and her colleagues were on the brink of something audacious, an innovative HIV vaccine trial across Africa, the bottom dropped out. To explain, let me rewind to early last year to a meeting in Zanzibar. The famous Zanzibar ship. Zanzibar is a tropical archipelago off the east coast of Africa. Penny Moore says it was crazy hot. those places where you just consider standing up and you break out in a sweat. The gathering took place in a hotel perched on the edge of a brilliant blue ocean.

There were researchers and clinicians from across Africa, and then there were the international scientific advisors. They grueled us to within an inch of our lives to make sure that we were doing the very best cutting-edge science we could do with the amount of money we had. That amount was $45 million, awarded by the United States Agency for International development to create a state-of-the-art vaccine to prevent HIV. The grant was intended to get teams across the continent to collaborate on developing a vaccine that would work in different African communities. The virus that they have in Kenya is not the same as the virus that we have in

Botswana. It's not the same as the virus that they have in Senegal. And so understanding how these vaccines will work for the local virus is what makes it relevant. At the meeting in Zanzibar, there was a real feeling of momentum. The excitement was through the roof. This is Penny Moore's colleague, Nono Imchise. We were at the beginning of something big. But just as the meeting was about to wrap up,

Penny Moore says the mood darkened. From the number of Americans, particularly checking their phones all of a sudden and talking to one another in little huddles. Something was wrong. Newly inaugurated President Trump had just signed an executive order freezing all foreign aid.

suddenly it seemed everything was up in the air. I remember at the end of the meeting, USAID colleagues saying to me, I'm not sure if I'll see you again. I completely underestimated how much it would gut the program. But more in her colleagues would soon find out. After returning to Johannesburg, she says the official stop work orders arrived from Washington.

Just weeks before the trials were to begin, everything came to a sudden halt. All the money was gone. In many ways, kind of had our legs cut off, even as we're beginning to run the sprint. Infectious disease specialist Linda Gail Becker is based at the University of Cape Town. When the funding collapsed, she says she cycled through the stages of grief. There's disbelief in the first instance.

Then there is emotion that basically is angry because we'd worked damn hard. We'd won this grant. And we were doing what we had said we would do. But gradually, Becker and her colleagues started saying... This matters too much to not finish the work. A period of frantic grant writing began. We brought out the begging bowl to say, this is important. Can you help us in some way?

Finally, they got funding from the South African Medical Research Council and the Gates Foundation, but it was a fraction of the original USAID grant and only focused inside South Africa, meaning they had to sacrifice studying how the vaccine might work against different versions of the virus within different African populations, Penny Moore. It's a bare-bones version. We will still get the answer,

but it's going to cost us time, years, which is not trivial, because people are getting infected with this virus constantly. Despite having to scale back, Moore says HIV vaccine research is farther along than it's ever been. She takes me back into that freezer room in her lab, which contains an embarrassment of science.

scientific riches, thanks in no small part to those 117 women and the samples they've donated over the years. These samples have taught us everything we know about HIV. And have revealed a veritable pot of scientific gold, a unique kind of antibody that showed up in the blood of a few of these women, something called a broadly neutralizing antibody. A broadly neutralizing antibody could stop my virus and could stop your virus and could stop the HIV virus from any other person. But it's difficult to coax the human immune system to produce these antibodies.

This vaccine trial is trying to figure out how to do that more easily. At last, after nearly a year of delays, the pared-down trial is getting underway. On the outskirts of Cape Town, a large brick building rises above Philippi Village, an impoverished township where HIV is rampant. A few levels up, I spot Amelia Mfiki, the community liaison officer for the vaccine trials. This is a great opportunity for South Africa to prove that we can do things in South Africa for South Africa with South African financing. Mfiki makes her way to a room where 20 or so young women from the community are gathered to hear about participating in the trial. HIV vaccine.

25-year-old Nandipa Mungo listens attentively. She says her community struggles with rape, sex traded for favors, unplanned pregnancies. Most of us are scared of getting HIV. Which is why she'd happily be involved in the research. I'm over the moon, man. I'm over the moon, yes. Because she's proud to be making a difference.

Yes, a big one, a big difference. So I ask her, if this team of researchers are able to find a vaccine, what would a world without HIV be like? Living free? Yeah. The first shots of the new vaccine trial started going into participants' arms this week. For NPR news, I'm R.A. Daniel, Cape Town, South Africa. Ari's reporting for this story was supported by a grant from the Pulitzer Center.

The Gates Foundation is a financial supporter of NPR. This episode was produced by Mallory Yu and Kira Joaquin. It was edited by Rebecca Davis and Courtney Dorney. Our executive producer is Sammy Yannigan. It's Consider This from NPR. I'm Juana Summers. For 47 years, Iranians have lived under a dictatorship many no longer want. Now the country may have reached a breaking point.

Iranians have recognized that they need to take matters into their own hands, pushing back against authority. We ask three central ones. questions about how Iran got here and what comes next. Listen to ThruLine on the NPR app or wherever you get your podcasts. This year's Oscar nominations are here and we are unpacking record-breaking nominations for sinners, plus nominations for Marty Supreme and won battle after another. And we'll talk about some of the surprises and snubs. Listen to pop culture happy hour in the NPR app or wherever you get your podcasts. Want to hear this podcast without sponsor? Thanks. Amazon Prime members can listen to Consider This sponsor-free through Amazon music. Or you can also support NPR's vital journalism and get Consider This Plus at plus.npr.org. That's plus.npr.org.